Morgan Stanley has released a research report providing an analysis of Vertex Pharmaceuticals (VRTX.US)'s $10 billion acquisition of Crinetics (CRNX.US). This acquisition will establish a fifth core business pillar for Vertex in endocrine drugs, thereby completing its therapeutic pipeline layout. According to the announcement, the buyout price of $85 per share represents a 102% premium over Crinetics' closing price on Monday. Vertex stated in its press release that, net of acquired cash, the deal values Crinetics at $8.8 billion and is expected to boost adjusted operating income by 2029. This transaction marks the largest in Vertex's history and is anticipated to close in the third quarter of 2026. The Morgan Stanley team forecasts that Crinetics will generate revenues of $183 million in 2027 and $830 million in 2030, accounting for approximately 1% and 4% of Vertex's total revenue, respectively.

Valuation Breakdown of Core Pipeline Assets

The report highlights that Crinetics possesses two key assets targeting rare endocrine diseases: the recently launched oral acromegaly treatment Paltusotine (formerly known as Palsonify); and the oral adrenocorticotropic hormone (ACTH) receptor antagonist Atumelnant, which is in Phase 3 trials for congenital adrenal hyperplasia (CAH) and Phase 2 trials for ACTH-dependent Cushing syndrome (ADCS). Combined with Vertex's internally developed stem cell therapy for type 1 diabetes, zimislecel, this creates a comprehensive rare endocrine disease portfolio. Vertex indicated that the combined peak sales potential for Crinetics' key drugs exceeds $5 billion. Paltusotine is expected to contribute to revenue growth immediately upon deal closure, while Atumelnant has the potential to generate billions from the CAH indication alone, with additional upside from the ADCS market. Morgan Stanley projects that by 2035, risk-adjusted sales for Paltusotine in acromegaly could reach $1 billion. The firm notes that as acromegaly is an orphan drug indication, Paltusotine would be exempt from certain U.S. tariff regulations announced in April 2026. Paltusotine is also undergoing a Phase 3 trial for carcinoid syndrome, though this is not a primary focus of the acquisition. Morgan Stanley further estimates that risk-adjusted peak sales for Atumelnant in CAH could be around $500 million. For the ADCS indication, the patient population is estimated at over 10,000 in the U.S. and approximately 15,000 overseas. It is noted that Morgan Stanley acted as a financial advisor to Vertex in facilitating this acquisition agreement.